BioAtla

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioAtla and other ETFs, options, and stocks.

About BCAB

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. 

CEO
Jay M. Short
CEOJay M. Short
Employees
76
Employees76
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2007
Founded2007
Employees
76
Employees76

BCAB Key Statistics

Market cap
56.77M
Market cap56.77M
Price-Earnings ratio
-0.69
Price-Earnings ratio-0.69
Dividend yield
Dividend yield
Average volume
1.21M
Average volume1.21M
High today
$0.99
High today$0.99
Low today
$0.82
Low today$0.82
Open price
$0.889
Open price$0.889
Volume
2.73M
Volume2.73M
52 Week high
$1.90
52 Week high$1.90
52 Week low
$0.24
52 Week low$0.24

Stock Snapshot

As of today, BioAtla(BCAB) shares are valued at $0.97. The company's market cap stands at 56.77M, with a P/E ratio of -0.69.

On 2025-11-17, BioAtla(BCAB) stock traded between a low of $0.82 and a high of $0.99. Shares are currently priced at $0.97, which is +17.9% above the low and -2.4% below the high.

BioAtla(BCAB) shares are trading with a volume of 2.73M, against a daily average of 1.21M.

In the last year, BioAtla(BCAB) shares hit a 52-week high of $1.90 and a 52-week low of $0.24.

In the last year, BioAtla(BCAB) shares hit a 52-week high of $1.90 and a 52-week low of $0.24.

People also own

Based on the portfolios of people who own BCAB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.